HOME >> BIOLOGY >> NEWS
Finding of a new molecular marker of resistance to chemotherapy in breast cancer

A collaborative study between the Hospital Clnic and the Hospital del Mar de Barcelona permits to establish a predictive factor in the resistance to chemotherapy in breast cancer and to establish possible therapeutic targets for the improvement of this treatment. This study has been published this month in the journal Endocrine-Related Cancer and is the result of the work initiated by Dr. Albanell's Group in Hospital Clnic, and finished in Hospital del Mar, where he leads the Unit of Oncology since almost a year. From the beginning, this study had the participation of the Unit of Pathology and Oncology of Hospital del Mar, and the Unit of Research on Cancer Experimental Therapeutics of Hospital del Mar-IMIM.

This study shows clinical evidence of the role played by the nuclear factor (NF)-ĸB in breast cancer and makes it a key target for new treatments, both to be aware of its existence and to predict a low chemotherapy response. If this is the case, the blocking of the factor prior to treatment is needed in order to increase the efficiency of treatment. The results of this study are the first to be published in which nuclear factor (NF)-ĸB, which promotes the survival of cells, has been specifically studied in order to observe its relevance in the prediction of response to chemotherapy.

Breast cancer is the most frequent cancer among women around the globe, with more than one million cases every year. It is the first cause of lost of potential years of life, and the second leading cause of cancer death among women. Breast cancer is one of the diseases causing more disorders to women in the developed countries because of the increase of new cases, its high mortality and the social repercussion it entails.

In Catalonia, the prevalence of breast cancer is of more than 50,000 women. Although the number of cases and incidence rate increase every year, mortality rate decreases. Survival of patients is improvin
'"/>

Contact: Rosa Manaut, Communication Hospital del Mar, Barcelona
rmanaut@imas.imim.es
34-618-509-885
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer
28-Jun-2006


Page: 1 2 3

Related biology news :

1. Finding protection from tumor growth in unexpected places
2. Finding the white wine difference
3. Finding an answer to Darwins Dilemma
4. Finding a cure for cancer: The holy grail of science
5. Finding the right mix: A biomaterial blend library
6. Finding paves way for better treatment of autoimmune disease
7. Finding about cellular microtubule rigidity could lead to development of new nano-materials
8. Findings by Einstein scientists reveal possible strategy against obesity, diabetes and infertility
9. Finding a cellular Neverland: How stem cells stay childlike
10. Finding a virus is not all bad news
11. Finding life on Mars and outer space begins by examining Earths inner space

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/31/2020)... (PRWEB) , ... July 30, 2020 , ... ... Research (SBIR) Phase II contract awarded by the Joint Science & Technology Office—Chemical ... this project is to develop, optimize, and scale-up a highly efficient mammalian cell ...
(Date:7/22/2020)... ... July 21, 2020 , ... ... in technology and compliance, announces a new solution to manage regulated workloads on ... layer of their technology stack complies with FDA and global regulations. USDM's new ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... ... August 13, 2020 , ... True Terpenes , the ... its Scientific Advisory Board (SAB) to research the medical potential of terpenes and the ... when combined with terpenes. The board is focused on expanding the recently launched line ...
(Date:8/12/2020)... ... August 12, 2020 , ... Inc. magazine ... global leader in FDA compliance consulting has been named on its annual Inc. ... list represents a unique look at the most successful companies within the American ...
(Date:7/31/2020)... ... , ... R3 Stem Cell International is now offering patients the opportunity to ... total, patients may choose which extremities they would like treated. , Several studies have ... 2016). At R3 International, umbilical cord tissue is obtained from a lab with a ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions ... that they have entered into a strategic partnership whereby Catalent will provide support ...
Breaking Biology Technology:
Cached News: